Pharmaceutical Media Training
High-stakes communication for pharmaceutical leaders — whether you are speaking at a medical congress, briefing a board, on CNBC after a trial readout, or preparing for an FDA announcement, we have a program built for you.
Why Pharmaceutical Leaders Need Industry-Specific Media Training
Pharmaceutical communication runs through some of the most specific regulatory guardrails in business. Every word a pharma spokesperson says about a product can implicate FDA promotional regulations, off-label considerations, or clinical-trial disclosure expectations. A single loose comment on CNBC can create a warning letter, an SEC inquiry, or a class-action exposure in the same week. Pharmaceutical media training is the preparation that keeps executives credible without creating regulatory, legal, or investor exposure. This work is led by Jess Todtfeld, a former producer at NBC, ABC, and FOX, the Guinness World Record holder for most media interviews in 24 hours, and a Certified Speaking Professional (CSP) who has trained professionals at Fortune 500 companies across biopharma, medical devices, and life sciences.
The FDA dimension is non-negotiable. FDA's Office of Prescription Drug Promotion and the broader regulatory framework around fair-balance, risk disclosure, and indication-specific language are always live during any public interview. Press interview training for pharma executives coordinates with regulatory affairs and medical-legal review so the spokesperson's language is the language the company is willing to publish.
Clinical trial readouts are a communication high-wire. The difference between a useful, investor-relevant description of trial data and an overclaim that invites a warning letter or a securities suit can be a single adjective. Training rehearses the exact register — accurate, measured, context-rich — that survives both regulatory and market scrutiny. Research published in JAMA and elsewhere has shown that media coverage of clinical trials regularly overstates results, and pharma executives carry a specific responsibility to keep their own language inside bounds.
Payer access and price stories are increasingly pressured. A reporter asking why a therapy is priced where it is will not be satisfied by generic language about value. Executives who can speak specifically about the clinical value, the patient population, and the access mechanisms outperform executives who deflect. On-camera pharma training builds that specific capability.
Finally, medical congresses, advisory boards, and investor meetings each reward overlapping but distinct skills. A CMO who presents rigorously at ASCO and then stumbles on a JPM panel is only half-prepared. Medical affairs media training builds the full cross-surface repertoire.
What Pharmaceutical Leaders Learn in Media Training
- Communicate clinical trial results with accuracy, context, and fair balance
- Navigate FDA-regulated language — on-label, indication-specific, and risk-disclosed
- Handle payer access and pricing questions with specific, patient-anchored answers
- Deliver medical congress presentations and advisory board sessions with keynote-level clarity
- Manage FDA announcement days — approvals, CRLs, and label changes — with rehearsed precision
- Respond to safety signal and adverse-event stories with composure and regulatory discipline
- Coordinate messaging across medical affairs, regulatory, communications, and investor relations
- Prepare clinical leaders, medical directors, and KOL-facing teams for their own on-camera moments
Common Media Challenges Pharma Leaders Face
The Trial Readout Interview
CNBC wants a live segment the morning of the Phase 3 announcement. Rehearse the precise, accurate, fair-balanced description that reinforces the data, handles the sell-side follow-up, and avoids the adjective that will trigger promotional scrutiny.
The FDA Decision Day
An approval, a CRL, or a label expansion is expected. Practice the statement that conveys the outcome accurately — including risks and limitations — and positions the company for the next milestone.
The Payer and Pricing Question
A reporter asks why the therapy costs what it does. Deliver the patient-anchored, value-specific answer that acknowledges the reality, describes the access mechanisms, and avoids the line that invites policy escalation.
The Safety Signal Story
An adverse-event signal has surfaced. Rehearse the composed, regulator-aligned response that acknowledges the signal, describes the evaluation process, and honors the patient community.
Why Train with Jess Todtfeld
Jess Todtfeld is a former producer at NBC, ABC, and FOX who has booked, produced, and coached thousands of on-camera interviews. He holds a Guinness World Record for the most media interviews in 24 hours and carries the Certified Speaking Professional (CSP) designation — the highest earned credential in professional speaking. He has trained professionals at Fortune 500 companies, regulated industries, nonprofits, and public-sector organizations through high-stakes press cycles.
His training is practical, on-camera, and tailored to the industry. Clients leave with a rehearsed message, a repeatable interview framework, and enough reps to walk into the hit with composure — whether it is a studio segment, a regulatory hearing, a conference keynote, or a hostile reporter at the door.
Frequently Asked Questions
Pharmaceutical media training prepares pharma executives, medical affairs leaders, and clinical spokespeople to communicate about trial readouts, FDA decisions, payer access, and safety events. It emphasizes regulator-aware language, fair balance, and on-camera composure.
A one-day intensive for a single executive typically runs in the mid-to-high four figures. Programs that include CMO, CCO, medical affairs, and IR together are quoted per scope.
Yes. Every pharma engagement coordinates with regulatory affairs and medical-legal review so the trained language is fully aligned with company policy.
Yes. Medical affairs and clinical development leader training is a core specialty and covers the specific demands of congress, KOL, and investigator-facing communication.
Training rehearses fair-balanced, indication-specific language and avoids the verbal habits that create promotional exposure. Regulatory affairs is a core partner in every engagement.
Yes. Crisis training for pharmaceutical safety events, CRLs, recalls, and litigation is a specialty and often delivered as a rapid-response engagement.
Yes. On-site delivery is common, including mock briefings timed to earnings cycles, FDA decision dates, or major congresses.
Most pharma executives reach strong on-camera performance after a one-day intensive. Refreshers tied to trial readout calendars and FDA decision dates are standard.
Related Training Programs
- Media training for healthcare executives
- Media training for medical professionals
- Crisis media training — for safety events, CRLs, and recalls
- Presentation training for pharmaceutical leaders — for congresses, advisory boards, and investor events
Ready to Strengthen Your Pharmaceutical Spokesperson Bench?
Build the FDA-aware, trial-ready, on-camera skills your executives need for the next readout, decision, or congress.